Immucell (ICCC) Long-Term Deferred Tax (2010 - 2025)
Immucell's (ICCC) quarterly Long-Term Deferred Tax came in at $17.6 million in Q4 2024, down 0.63% YoY from $17.8 million in Q1 2024, and down 0.63% on a QoQ basis from $17.8 million in Q4 2023.
Immucell (ICCC) Long-Term Deferred Tax (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 15 years of Long-Term Deferred Tax data on file, last reported at $17.6 million in Q4 2024.
- Quarterly Long-Term Deferred Tax fell 0.63% year-over-year to $17.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $17.6 million (down 0.63% YoY) and the FY2024 annual result came in at $17.6 million, down 0.63% from the prior year.
- Long-Term Deferred Tax fell to $17.6 million in Q4 2024, from $17.8 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $17.8 million in Q4 2023 to a low of $78087.0 in Q4 2021.
- A 5-year average of $7.8 million and a median of $3.3 million in 2022 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2020 — Long-Term Deferred Tax slumped 82.36% — and 2022, when it jumped 4072.78%.
- Tracing ICCC's Long-Term Deferred Tax over 5 years: stood at $442632.0 in 2020, then tumbled by 82.36% to $78087.0 in 2021, then jumped by 4072.78% to $3.3 million in 2022, then jumped by 445.04% to $17.8 million in 2023, then slipped by 0.63% to $17.6 million in 2024.
- The last three Long-Term Deferred Tax figures came in at $17.6 million (Q4 2024), $17.8 million (Q4 2023), and $3.3 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.93 Mn |
| Dec 31, 2024 | 17.65 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Dec 31, 2021 | 78,087.00 |
| Dec 31, 2020 | 442,632.00 |
| Dec 31, 2019 | 2.51 Mn |
| Dec 31, 2018 | 2.49 Mn |
| Jun 30, 2018 | 563,252.00 |
| Mar 31, 2018 | 504,236.00 |
| Dec 31, 2017 | 472,726.00 |
| Sep 30, 2017 | 189,968.00 |
| Jun 30, 2017 | 21,051.00 |
| Dec 31, 2016 | 201,003.00 |
| Sep 30, 2016 | 290,074.00 |
| Jun 30, 2016 | 287,893.00 |
| Mar 31, 2016 | 266,717.00 |
| Dec 31, 2015 | 452,117.00 |
| Sep 30, 2015 | 543,602.00 |
| Jun 30, 2015 | 773,326.00 |